Physician

Daniel F Ikemiyashiro, M.D.

According to 2025 Medicare claims, Daniel Ikemiyashiro, M.D. (NPI: 1801837208) practices nephrology in the Merced, CA market, with the plurality of this provider's patient population coming from Merced, CA. This provider's primary affiliated billing organization is THE NEPHROLOGY GROUP, INC. (NPI: 1205906229; TIN: 770383758) and primary practice location at 95348-9408.

Ikemiyashiro's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 721 traditional Medicare patients, billed 6,644 HCPCS/CPT codes, and received $461,358 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 4,108 prescription claims across 634 beneficiaries totaling $1,169,795 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 260 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $748,534 to $1,169,795. In contrast, DME billing represents a smaller volume and declined steadily, from $15,358 to $2,454.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	915	31,578	$468,588
2016	878	13,855	$535,137
2017	920	21,835	$575,142
2018	882	26,610	$673,738
2019	847	20,129	$577,250
2020	722	14,712	$512,754
2021	669	9,659	$547,600
2022	779	6,593	$553,420
2023	755	6,500	$523,264
2024	721	6,644	$461,358

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	417	5,671	$748,534
2016	389	4,861	$883,127
2017	397	4,987	$885,677
2018	428	4,655	$584,662
2019	405	3,975	$427,939
2020	408	3,942	$474,154
2021	438	3,801	$520,697
2022	527	3,371	$683,237
2023	628	4,169	$1,219,015
2024	634	4,108	$1,169,795

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	45	324	$17,242
2016	36	273	$19,818
2017	19	203	$17,334
2018	20	247	$16,681
2019	16	263	$26,365
2020	17	374	$22,636
2021	N/R	234	$10,547
2022	N/R	184	$6,695
2023	N/R	146	$3,094
2024	N/R	260	$5,843

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	439	1,003	$66
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	389	651	$13
80053	Blood test, comprehensive group of blood chemicals	192	400	$10
36415	Insertion of needle into vein for collection of blood sample	196	426	$9
83735	Magnesium level	195	413	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	329	20,366	$363,909
Xphozah	Tenapanor Hcl	58	1,920	$178,839
Jardiance	Empagliflozin	123	7,313	$131,274
Kerendia	Finerenone	67	3,450	$73,120
Velphoro	Sucroferric Oxyhydroxide	17	938	$71,349

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7515	Cyclosporine, oral, 25 mg	N	N/R	13	$1,382
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	70	$1,245
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	51	$1,151
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	54	$984
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	57	$702

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Daniel F. Ikemiyashiro, M.D.?

Tedicare shows public-source Medicare data for Daniel F. Ikemiyashiro, M.D. (NPI 1801837208), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Daniel F. Ikemiyashiro, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Daniel F. Ikemiyashiro, M.D.?

Daniel F. Ikemiyashiro, M.D. is linked to THE NEPHROLOGY GROUP, INC. (billing NPI 1205906229) in the available physician profile data.

Does Daniel F. Ikemiyashiro, M.D. have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.